ONCS Logo
ONCS
OncoSec Medical Inc
$0.28
0.00%
Company Details
Name

OncoSec Medical Inc

Website

http://oncosec.com/

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

Categories

Commercial ServicesMiscellaneous Commercial ServicesHealth ServicesMedical/Nursing ServicesManufacturingPharmaceutical Preparation Manufacturing

CEO

Daniel O'Connor

Employees

88,300

Description

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar

Stock Quote
Market Cap

$1.65M

52 Week High

$0.28

PE Ratio

-

52 Week Low

-

EPS

-

Shares Outstanding

5.96M

Dividend Yield

-

Dividend Per Share

-

Company Details
Name

OncoSec Medical Inc

Website

http://oncosec.com/

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

Categories

Commercial ServicesMiscellaneous Commercial ServicesHealth ServicesMedical/Nursing ServicesManufacturingPharmaceutical Preparation Manufacturing

CEO

Daniel O'Connor

Employees

88,300

Description

oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar

Latest News
Related Stocks